Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.07.2021 | Case report

Nivolumab

Immune-related meningoencephalitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Pous A, et al. Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: A case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen. Translational Lung Cancer Research 10: 1917-1923, No. 4, Apr 2021. Available from: URL: http://doi.org/10.21037/tlcr-20-1315 Pous A, et al. Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: A case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen. Translational Lung Cancer Research 10: 1917-1923, No. 4, Apr 2021. Available from: URL: http://​doi.​org/​10.​21037/​tlcr-20-1315
Metadaten
Titel
Nivolumab
Immune-related meningoencephalitis: case report
Publikationsdatum
01.07.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-99232-4

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Ribavirin

Case report

Cerliponase-alfa

Case report

Multiple drugs